From Bi to Trispecific Antibodies: Reimagining the Next Generation of ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

From Bi to Trispecific Antibodies: Reimagining the Next Generation of ADCs

2:30 pm - Tuesday 13th October 2026

Utilizing bi- and tri-specific matrix screening to rapidly identify optimal antibody pairings
Exploring B-Body bispecific and T-Body trispecific antibodies that exhibit good killing from in vitro ADC assays across a diverse set of breast cancer cell lines
Showcasing that multi-target ADCs demonstrate broader and more durable tumor control in vivo, including in drug-resistant cell populations that evade monospecific therapy

Speakers:

Bonnie Hammer

Bonnie Hammer

Executive Vice President - Research & Development

Invenra Inc.